Abstract:Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders. Voltage-gated sodium channels (Na V s) are responsible for action potential initiation and transmission of pain signals. Na V 1.8 is specifically expressed in peripheral nociceptors and has been genetically and pharmacologically validated as a human pain target. Selective inhibition of Na V 1.8 can ameliorate pain while minimizing effects on other Na V isoforms essential for cardiac, respiratory, and central nervous system physiology. Here we present the pharmacology, interaction site, and mechanism of action of LTGO-33, a novel Na V 1.8 small molecule inhibitor. LTGO-33 inhibited Na V 1.8 in the nM potency range and exhibited over 600-fold selectivity against human Na V 1.1–Na V 1.7 and Na V 1.9. Unlike prior reported Na V 1.8 inhibitors that preferentially interacted with an inactivated state via the pore region, LTGO-33 was state-independent with similar potencies against closed and inactivated channels. LTGO-33 displayed species specificity for primate Na V 1.8 over dog and rodent Na V 1.8 and inhibited action potential firing in human dorsal root ganglia neurons. Using chimeras combined with mutagenesis, the extracellular cleft of the second voltage-sensing domain was identified as the key site required for channel inhibition. Biophysical mechanism of action studies demonstrated that LTGO-33 inhibition was relieved by membrane depolarization, suggesting the molecule stabilized the deactivated state to prevent channel opening. LTGO-33 equally inhibited wild-type and multiple Na V 1.8 variants associated with human pain disorders. These collective results illustrate LTGO-33 inhibition via both a novel interaction site and mechanism of action previously undescribed in Na V 1.8 small molecule pharmacologic space. SIGNIFICANCE STATEMENT Na V 1.8 sodium channels primarily expressed in peripheral pain-sensing neurons represent a validated target for the development of novel analgesics. Here we present the selective small molecule Na V 1.8 inhibitor LTGO-33 that interdicts a distinct site in a voltage-sensor domain to inhibit channel opening. These results inform the development of new analgesics for pain disorders.

Structural basis for high-voltage activation and subtype-specific inhibition of human Na v 1.8.

Structural basis for high-voltage activation and subtype-specific inhibition of human Na<sub>v</sub>1.8

Structural basis for Na V 1.7 inhibition by pore blockers

High-resolution Structures of Human Nav1.7 Reveal Gating Modulation Through Α-Π Helical Transition of S6IV.

Structural mechanism of voltage-gated sodium channel slow inactivation.

Unwinding and spiral sliding of S4 and domain rotation of VSD during the electromechanical coupling in Na<sub>v</sub>1.7

Structure of the Human Voltage-Gated Sodium Channel Nav1.4 in Complex with Β1.

Structures of Human Nav1.7 Channel in Complex with Auxiliary Subunits and Animal Toxins.

Cryo-EM structure of human voltage-gated sodium channel Na <sub>v</sub> 1.6

Structural Mapping of Na V 1.7 Antagonists

Structural basis for the modulation of voltage-gated sodium channels by animal toxins

Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors

Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2

Cryo-EM structure of human voltage-gated sodium channel Nav1.6

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Regulation and drug modulation of a voltage-gated sodium channel: Pivotal role of the S4–S5 linker in activation and slow inactivation

Structure of human NaV1.6 channel reveals Na+ selectivity and pore blockade by 4,9-anhydro-tetrodotoxin

Structure of human NaV1.6 channel reveals Na<sup>+</sup>selectivity and pore blockade by 4,9-anhydro-tetrodotoxin

Unwinding and spiral sliding of S4 and domain rotation of VSD during the electromechanical coupling in Nav1.7

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action

Structural basis of inhibition of human NaV1.8 by the tarantula venom peptide Protoxin-I